Contact Us
We build immune intelligence for biotech, pharma and clinical research teams — turning immune repertoire data into the signals that guide patient stratification, treatment monitoring, and drug development.
The adaptive immune system records a lifetime of exposures: infections, vaccines, and disease. Your future is written, in part, by your past.
Cracking that code means detecting disease years earlier, personalizing treatment to an individual's immune history, and giving drug developers a way to know, before a trial even starts, who is likely to respond.
Immunotherapy is the most promising treatment approach for cancer and autoimmune disease. However, without a way to predict who will respond, trials fail, and effective therapies never reach patients.
Knowing who to enroll can be the difference between a trial that succeeds and one that doesn't.
Cognate integrates computational immunology, high-throughput sequencing, and machine learning to decode immune repertoires.
Cognate turns raw sequencing data into signals that guide diagnostics, treatment selection, and personalized medicine for biotech, pharma and clinical partners.
High-throughput comprehensive profiling of T-cell populations across cohorts and timepoints, from a single blood draw, capturing immune dynamics as they unfold.
A foundation model trained on our large, curated immune repertoire dataset embeds each patient's repertoire and situates it against our full population-scale atlas, surfacing patterns no single-disease marker was designed to catch.
A literature-grounded reasoning layer runs statistical analysis over the contextualized repertoire and writes an interpretive report, answering the questions trial teams actually ask, like why is this patient an outlier or what's the likelihood of an adverse event, and what's driving it.
Chief Executive Officer
Computational immunologist and T-cell expert. Pioneering new methods for understanding adaptive immunity.
Chief Technology Officer
AI researcher and causal inference expert. Building the bridge between machine learning theory and immune system understanding.
Professor of Physics, Université de Montréal
Pioneer in computational modeling of the immune system and T-cell recognition.
Co-founder, Valence Labs (acquired by Recursion)
Scientist and founder in AI and drug discovery.
Cognate is part of the
Launchpad program
